Explore the words cloud of the TiMaScan project. It provides you a very rough idea of what is the project "TiMaScan" about.
The following table provides information about the project.
ACADEMISCH ZIEKENHUIS LEIDEN
|Coordinator Country||Netherlands [NL]|
|Total cost||2˙500˙000 €|
|EC max contribution||2˙500˙000 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2016-11-01 to 2021-10-31|
Take a look of project's partnership.
|1||ACADEMISCH ZIEKENHUIS LEIDEN||NL (LEIDEN)||coordinator||2˙500˙000.00|
In the ageing European population, cancer has become the most common cause of death. Consequently, screening programs aim at early detection of cancer, while scanning/imaging technologies, serum assays and regular biopsies aim at monitoring of treatment effectiveness to improve cure rates and increase quality-of-life, thereby also attempting to reduce health care costs. However, in many cases the screening and monitoring methods do not provide sufficient sensitivity and specificity. Consequently novel diagnostic techniques are required. Completely Novel Concept: Sensitive intra-tissue total body scanning is continuously performed by our immune cells, particularly by monocytes and macrophages. Tissue macrophages (TiMas) continuously phagocytize and digest apoptotic cells and tissue debris. In cancer, many more TiMas are present to keep the involved tissue debris-free. When TiMas have fulfilled their local tissue-cleaning task, they can migrate via lymph vessels to lymph nodes and potentially recirculate to the blood stream, where they can be detected by flow cytometry and evaluated for the contents of their phagolysosomes. With State-of-the-Art technologies, this high-risk project aims to unravel phagocytosis of cancer cells, their digestion into tissue-specific and/or cancer-specific protein fragments, the migration/recirculation of TiMas to blood, and the detection of intra-phagosomal protein fragments in blood TiMas by antibodies. Building on this information, flowcytometric scanning of blood TiMas (TiMaScan) will be developed into a novel tool for early diagnosis and treatment monitoring in oncology, focusing on colon, lung, breast and prostate cancer. TiMaScan diagnostics will be minimally-invasive (~1ml of blood), rapid, accurate, broadly available and cost-effective, only requiring a flowcytometer. The TiMaScan Concept might also be applicable for early diagnosis and disease monitoring in other medical fields, such as neurodegenerative and infectious diseases.
|year||authors and title||journal||last update|
Daniela Damasceno, Cristina Teodosio, Wouter B.L. van den Bossche, MartÃn Perez-Andres, Sonia Arriba-MÃ©ndez, Luis MuÃ±oz-Bellvis, Alfonso Romero, Juan F. Blanco, Ana Remesal, Noemi Puig, Sergio Matarraz, JosÃ© Luis Vicente-VillardÃ³n, Jacques J.M. van Dongen, Julia Almeida, Alberto Orfao
Distribution of subsets of blood monocytic cells throughout life
published pages: , ISSN: 0091-6749, DOI: 10.1016/j.jaci.2019.02.030
|Journal of Allergy and Clinical Immunology||2019-08-05|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TIMASCAN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "TIMASCAN" are provided by the European Opendata Portal: CORDIS opendata.